Background: Regarding mediastinal N-staging in lung cancer patients, computed tomography (CT), magnetic resonance imaging (MRI), and integrated 18 Fluorine-fluorodeoxyglucose-positron emission tomography/CT ( 18 F-FDG-PET/CT) are the most widespread imaging methodologies in clinical routine. Objectives: In order to further extract information from non-invasive staging, we evaluated the use of 18 F-FDG-PET/CT and dynamic contrast enhanced (DCE) and diffusion-weighted imaging (DWI) MRI using histopathology as the diagnostic gold standard. Patients and Methods: A total number of 50 patients had undergone MRI of the chest within two weeks prior to surgery for histopathological proof. DCE-MRI was evaluated on the basis of region of interest (ROI)-based signal intensity/time (SI/T) curves in the respective mediastinal lymph nodes (LNs). In total, 28 LNs could be allocated to the corresponding histopathological findings, as well as to corresponding findings in 18 F-FDG-PET/CT. Results: Malignant LNs presented with significantly higher FDG uptake in PET. Significant differences between malignant and benign LNs were found for DCE-MRI regarding the parameters MaxE, 4-minutes value, SE, EP and EP/MaxE. In DWI-MRI, malignant LNs presented with significantly lower signal intensity compared to benign LNs (p < 0.01). An apparent diffusion coefficient (ADC) threshold of 1528 mm 2 /s was found to exclude malignancy for LNs that are above the threshold. Conclusion: 18 F-FDG-PET in addition with MRI that includes DWI might improve mediastinal N-staging, which is of interest in cases of FDG-equivocal LNs. An ADC threshold of 1528 mm 2 /s might potentially help to further classify LNs with indefinite PET-findings. DCE-MRI of mediastinal LNs seems not yet to be approved for clinical routine.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.